Cargando…

Tivozanib in renal cell carcinoma: a new approach to previously treated disease

Targeted therapies have been a mainstay of the renal cell carcinoma (RCC) treatment paradigm for the better part of two decades. Multikinase inhibitors of the vascular endothelial growth factor receptor tyrosine kinases (VEGF-TKIs) comprise nearly all targeted therapies in RCC, having been prospecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salgia, Nicholas J., Zengin, Zeynep B., Pal, Sumanta K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Challenging Dogma: New Evidence to Guide Practice in Urologic Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249546/ https://www.ncbi.nlm.nih.gov/pubmed/32547647 http://dx.doi.org/10.1177/1758835920923818

Ejemplares similares

Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma
por: Wu, Qiuji, et al.
Publicado: (2022)

Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
por: Rassy, Elie, et al.
Publicado: (2020)

Cytoreductive nephrectomy in the current treatment algorithm
por: Kuusk, Teele, et al.
Publicado: (2019)

Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET?
por: Alipour, Ramin, et al.
Publicado: (2019)

PARP inhibitor combinations in prostate cancer
por: Pezaro, Carmel
Publicado: (2020)

Combination therapy in metastatic hormone-sensitive prostate cancer: is three a crowd?
por: Davis, Ian D.
Publicado: (2022)

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3
por: Meza, Luis, et al.
Publicado: (2022)

Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma
por: Sakellakis, Minas, et al.
Publicado: (2023)

Tivozanib in the treatment of renal cell carcinoma
por: Hepgur, Mehmet, et al.
Publicado: (2013)

SEOM clinical guidelines for the treatment of renal cell carcinoma
por: Bellmunt, J., et al.
Publicado: (2014)

A hands-on tutorial on network and topological neuroscience
por: Centeno, Eduarda Gervini Zampieri, et al.
Publicado: (2022)

An observational, multicentre study of cabazitaxel in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel (CAPRISTANA)
por: Carles, Joan, et al.
Publicado: (2018)

Bilateral Renal Mucor Mycosis Presenting as Anuria in a Covid 19 Recovered Patient: A Case Report and Review of Literature
por: Vaddi, Surya Prakash, et al.
Publicado: (2022)

Chronic kidney disease and small renal tumors: What urologists should know?
por: Muruganandham, K., et al.
Publicado: (2009)

Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives
por: Rodenburg, RJ, et al.
Publicado: (2019)

Sorafenib in the management of metastatic renal cell carcinoma
por: Guevremont, C., et al.
Publicado: (2009)

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial
por: Barata, Pedro C, et al.
Publicado: (2023)

Impact of previous open renal surgery on the outcomes of subsequent percutaneous nephrolithotomy: a meta-analysis
por: Hu, Henglong, et al.
Publicado: (2016)

Renal Cell Carcinoma and Prognostic Factors Predictive of Survival
por: Sorbellini, M., et al.
Publicado: (2009)

State-of-the-art treatment of metastatic renal cell carcinoma
por: Heng, D.Y.C., et al.
Publicado: (2009)

Review of guidelines on the treatment of metastatic renal cell carcinoma
por: Soulières, D.
Publicado: (2009)

Sex Differences in Renal Cell Carcinoma: The Importance of Body Composition
por: Dahlmann, Sebastian, et al.
Publicado: (2022)

Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions
por: Govindarajan, Ameish, et al.
Publicado: (2022)

Role of cytokine therapy for renal cell carcinoma in the era of targeted agents
por: Koneru, R., et al.
Publicado: (2009)

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
por: Cowey, C Lance
Publicado: (2013)

Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma
por: Yalcin, Suayib, et al.
Publicado: (2019)

Radical or simple nephrectomy in localized renal cell carcinoma: what is a choice?
por: Shulyak, Alexander, et al.
Publicado: (2011)

Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours
por: Wah, Tze M, et al.
Publicado: (2014)

Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma
por: Kapoor, A., et al.
Publicado: (2009)

Targeted therapies for renal cell carcinoma: more gains from using them again
por: Gan, H.K., et al.
Publicado: (2009)

Impact of hospital nephrectomy volume on intermediate‐ to long‐term survival in renal cell carcinoma
por: Hsu, Ray C. J., et al.
Publicado: (2019)

Time trends in service provision and survival outcomes for patients with renal cancer treated by nephrectomy in England 2000–2010
por: Hsu, Ray C. J., et al.
Publicado: (2018)

SUPPORT Tools for evidence-informed health Policymaking (STP) 1: What is evidence-informed policymaking?
por: Oxman, Andrew D, et al.
Publicado: (2009)

SUPPORT Tools for evidence-informed health Policymaking (STP) 10: Taking equity into consideration when assessing the findings of a systematic review
por: Oxman, Andrew D, et al.
Publicado: (2009)

SUPPORT Tools for evidence-informed Policymaking in health 11: Finding and using evidence about local conditions
por: Lewin, Simon, et al.
Publicado: (2009)

SUPPORT Tools for evidence-informed health Policymaking (STP) 12: Finding and using research evidence about resource use and costs
por: Oxman, Andrew D, et al.
Publicado: (2009)

SUPPORT Tools for evidence-informed health Policymaking (STP) 13: Preparing and using policy briefs to support evidence-informed policymaking
por: Lavis, John N, et al.
Publicado: (2009)

SUPPORT Tools for evidence-informed health Policymaking (STP) 14: Organising and using policy dialogues to support evidence-informed policymaking
por: Lavis, John N, et al.
Publicado: (2009)

SUPPORT Tools for evidence-informed health Policymaking (STP) 15: Engaging the public in evidence-informed policymaking
por: Oxman, Andrew D, et al.
Publicado: (2009)

SUPPORT Tools for evidence-informed health Policymaking (STP) 17: Dealing with insufficient research evidence
por: Oxman, Andrew D, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_jt4e09rofejj836kc0051nmg3i